Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer

FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma

Bhupinder Mann, John R. Johnson, Martin H. Cohen et al. · The Oncologist · 2007 · 1.3K citations · Full text

Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages

Jennifer L. Guerriero, Alaba Sotayo, Holly Ponichtera et al. · Nature · 2017 · 540 citations · Full text

Breast Oncology, Medicine, Immunology +9

HDACs link the DNA damage response, processing of double-strand breaks and autophagy

Thomas Robert, Fabio Vanoli, Irene Chiolo et al. · Nature · 2011 · 409 citations · Full text

Chromatin, Genome Instability, Cell Autophagy +10

Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability

Benjamin Lauffer, Robert Mintzer, Rina Fong et al. · Journal of Biological Chemistry · 2013 · 400 citations · Full text

An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential

Liqin Wang, Rodrigo Leite de Oliveira, Sanne C.F.A. Huijberts et al. · Cell · 2018 · 336 citations · Full text

Tumor Biology, Acquired Vulnerability, Medicine +7